Abstract Background: The Pancreatic Cancer Detection Consortium (PCDC) is an NCI-sponsored initiative to improve detection of early-stage pancreatic ductal adenocarcinoma (PDAC). A key strategy in this initiative is to develop prospective, multi-center, longitudinal biospecimen collections from individuals without PDAC who are at high-risk of PDAC due to family history, germline variants, or the presence of pancreatic cystic lesions. The biospecimen collections, linked to clinically relevant data, will enable Phase 3 biomarker validation studies. Methods: The PCDC currently includes 10 funded Research Units (RUs): City of Hope/TGen, Dana Farber Cancer Institute, Johns Hopkins Medical Institute, Mayo Clinic/University of Pennsylvania, MD Anderson Cancer Center, Oregon Health and Science University, University of Nebraska, University of Pittsburgh Medical Center, University of California (UC) San Diego, UC San Franciso. Non-protected patient health information and biospecimen data is logged into a central Medidata Rave® database managed by a Management and Data Coordination Unit (MDCU) at Mayo Clinic (NCT06271291). Biospecimens collected include blood and pancreatic cyst fluid. Two options for blood collections exist: 1) 20 mL EDTA, 10 mL no additive if samples can be frozen within 4 hours of collection; 2) 10 mL EDTA, 10 mL Streck, 10 mL no additive if samples cannot be frozen within 4 (but less than 12) hours. Cyst fluid (up to 1000 uL), if available as clinical residual, will be obtained at the time of clinically indicated operative resection or endoscopic ultrasound guided aspiration procedures. All samples must be processed per standardized methods outlined in the lab manual and aliquoted into 500 uL (blood) or 100 uL (cyst fluid) units and frozen (-70oC). Long-term biospecimen storage will be set up at NCI Frederick National Laboratory (FNL). Single Institutional Review Board (sIRB) oversight is provided by Mayo Clinic. A collaborative research agreement has been executed to allow sharing of data and biospecimens between and within PCDC RU members, the MDCU, NCI and NCI FNL. Results: The enrollment of patients began February 7, 2025 with additional sites joining as necessary sIRB reliance documents and training is completed. The protocol is approved for up to 30, 000 patients, age 18 years and older. 14 have been enrolled from 1 site as of July 10, 2025. Study endpoints include diagnosis of PDAC, death or complete pancreatectomy for non-PDAC reasons. Biospecimens and questionnaires will be collected annually. Summary and Future Plans: The PCDC has designed a Phase 3 biobank following EDRN study design principles. Biospecimens will be stored at NCI FNL. Access to the biobank resource will be overseen by the PCDC Steering Committee. We anticipate this being a rich Phase 3 biospecimen resource for the pancreatic cancer early detection research community. Citation Format: Janet E. Olson, Shounak Majumder, Jennifer J. Brooks, Emily J. Kirsch, Bridget H. Schmidt, Bill R. Bamlet, Erin E. Carlson, Ann L. Oberg. On the development of the Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts biobank abstract. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85 (18Suppl₃): Abstract nr B069.
Olson et al. (Sun,) studied this question.